These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30289405)

  • 21. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.
    Huang B; Ghatge MS; Donkor AK; Musayev FN; Deshpande TM; Al-Awadh M; Alhashimi RT; Zhu H; Omar AM; Telen MJ; Zhang Y; McMahon TJ; Abdulmalik O; Safo MK
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
    Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
    Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting HbS Polymerization.
    Ferrone FA
    Semin Hematol; 2018 Apr; 55(2):53-59. PubMed ID: 30616807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice.
    Dufu K; Williams AT; Muller CR; Walser CM; Lucas A; Eaker AM; Alt C; Cathers BE; Oksenberg D; Cabrales P
    Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H400-H411. PubMed ID: 34213392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.
    Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS
    Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting sickle cell disease root-cause pathophysiology with small molecules.
    Saunthararajah Y
    Haematologica; 2019 Sep; 104(9):1720-1730. PubMed ID: 31399526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
    Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
    Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent.
    Iyamu EW; Turner EA; Asakura T
    Br J Haematol; 2002 Jul; 118(1):337-43. PubMed ID: 12100171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.
    Nakagawa A; Lui FE; Wassaf D; Yefidoff-Freedman R; Casalena D; Palmer MA; Meadows J; Mozzarelli A; Ronda L; Abdulmalik O; Bloch KD; Safo MK; Zapol WM
    ACS Chem Biol; 2014 Oct; 9(10):2318-25. PubMed ID: 25061917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
    Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.
    Estepp JH
    Am J Hematol; 2018 Mar; 93(3):326-329. PubMed ID: 29352729
    [No Abstract]   [Full Text] [Related]  

  • 35. Crystal structure of carbonmonoxy sickle hemoglobin in R-state conformation.
    Ghatge MS; Ahmed MH; Omar AS; Pagare PP; Rosef S; Kellogg GE; Abdulmalik O; Safo MK
    J Struct Biol; 2016 Jun; 194(3):446-50. PubMed ID: 27085422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.
    Hebbel RP; Hedlund BE
    Am J Hematol; 2018 Mar; 93(3):321-325. PubMed ID: 29150874
    [No Abstract]   [Full Text] [Related]  

  • 37. Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin.
    Kim-Shapiro DB; King SB; Bonifant CL; Kolibash CP; Ballas SK
    Biochim Biophys Acta; 1998 Mar; 1380(1):64-74. PubMed ID: 9545536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
    Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R
    Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.